NEW YORK - Fitness experts are shining a new light on group classes from Zumba to yoga because they believe the right lighting can transform the four walls of a fitness studio from a dance party to a meditation space, and back again.
DUBLIN - Elan announced its second major drug deal inside a week on Monday and said it would buy back more shares as it continues to bat against a $5.7 billion takeover bid from U.S. investor Royalty Pharma.
NEW YORK (Reuters Health) - Boys who are diagnosed with attention-deficit/hyperactivity disorder (ADHD) in elementary school are more likely to grow up to be obese adults than those who don't have the condition, a new study suggests.
NEW YORK (Reuters Health) - A newer version of the whooping cough vaccine doesn't protect kids as well as the original, which was phased out in the 1990s because of safety concerns, according to a new study.
JAKARTA - When a sick Indonesian baby died after 10 hospitals in Jakarta turned her family away in February, critics blamed a pilot health insurance scheme that had overwhelmed the city's public hospitals.
- Generic drugmaker Actavis Inc, which has been the subject of intense takeover speculation, said on Monday that it had struck a deal to buy specialty pharmaceuticals company Warner Chilcott Plc for $8.5 billion in stock.
- XenoPort Inc said it will stop developing its experimental multiple sclerosis treatment after data from a late-stage trial showed the drug did not improve patients' condition significantly compared with a placebo.
LONDON - Saudi Arabia has reported another case of infection in a concentrated outbreak of a new strain of a virus that emerged in the Middle East last year and spread into Europe, the World Health Organization (WHO) said on Saturday.
COPENHAGEN - Danish pharmaceutical group Lundbeck and Japanese partner Takeda said on Saturday that data from clinical phase III studies with the antidepressant vortioxetine had shown significant improvement in patients' symptoms.
LONDON - Bayer's acne pill Diane 35 and its generic versions are safe to use in certain women when other options have failed, the European Medicines Agency said on Friday.